Abstract 195P
Background
Ferroptosis is a type of programmed cell death dependent on iron metabolism distinct from necrosis and apoptosis. In pancreatic ductal adenocarcinomas (PDAC), studies have noted that ferroptosis signatures are also associated with survival. However, no studies have attempted to find histological correlates which might suggest a ferroptosis process occurring.
Methods
PDACs from the Cancer Genome Atlas (TCGA) Pan-Cancer were used. Clinicopathological, DNA, histological slides, and mRNA expression data were extracted with the GDC Data Transfer Tool. A scree plot was generated to determine the optimal number of clustering groups based on ferroptosis molecular signatures. A K-means clustering approach was used in STATA. Groups of less than 5 patients were excluded. The ferroptosis-based clusters were correlated to clinical, histological, molecular, and survival parameters. Gene Set Enrichment Analysis (GSEA) was also performed by identified cluster. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
175 PDAC cases were used from the TCGA. Optimal K-means clustering identified 4 distinct ferroptosis signature-based PDAC groups, which differed in gene expression. Group 1 (n=47) showed improved overall survival by log-rank analysis versus other 3 groups (p<0.05). There was no significant difference in age, sex distribution, tumor grade, necrosis or staging between Group 1 and other groups. Over-expressed genes in ferroptosis-based group 1 include MAP3K14, TNFAIP3, CYGb; underexpressed genes in Group 1 include EMC2, ZFAS1, CYP4F8. GSEA showed downregulation of EET, DHET and HETE synthesis, and upregulation of RNA metabolism, cell cycle and mitotic activity in Group 1 vs other 3 groups.
Conclusions
A comprehensive multimodal approach to ferroptosis expression signatures highlights a clinical impact on overall survival. However, after post-hoc analysis by two pathologists, no histological marker was identified to be significantly associated with ferroptosis signatures. Genes involved in group 1 modulate nF-κB signaling, target lipid peroxidation, and inhibit GPX4 function. Further ancillary testing of ferroptosis pathway in PDACs is warranted.
Editorial acknowledgement
Legal entity responsible for the study
Vincent Quoc-Huy Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract